Surge in Testosterone Prescriptions for Women Amid Accessibility Challenges

A recent analysis reveals a significant increase in testosterone prescriptions for women, with a reported 146% rise between January 2023 and July 2026. This surge is particularly notable among postmenopausal women experiencing symptoms associated with menopause. However, the increase in prescriptions has coincided with reports of delays and denials from pharmacies, highlighting ongoing barriers to access for patients seeking this treatment.

Currently, there are no testosterone products approved by the Food and Drug Administration (FDA) specifically for women. This lack of FDA-approved options can complicate the prescribing process, as many healthcare providers are left to prescribe testosterone off-label. While there is clinical support for testosterone therapy in treating hypoactive sexual desire disorder (HSDD) in postmenopausal women, concerns persist over the lack of formal approval for female-specific formulations.

In response to the growing demand for testosterone therapy among women, the FDA recently urged manufacturers to conduct research that could lead to the approval of testosterone products designed specifically for females. This push for more data comes amidst an increasing acknowledgment of the potential benefits of testosterone in treating sexual desire issues, though its efficacy for other menopause-related symptoms remains uncertain.

Organizations like the Menopause Society endorse the use of testosterone specifically for HSDD in postmenopausal women. However, they caution against its use for other menopause symptoms, such as fatigue or mood swings. Dr. Stephanie Faubion, Director of the Mayo Clinic Center for Women’s Health, noted that while testosterone levels decline with age, this decline is not uniquely tied to menopause. She emphasized that testosterone has not been proven to alleviate other menopause-related concerns, despite some healthcare practitioners prescribing it off-label for those purposes.

HSDD is a prevalent condition among women, defined by persistently low sexual desire that leads to personal distress. Studies indicate that a significant percentage of naturally menopausal women experience low sexual desire, with HSDD affecting about 1 in 8 women aged 45 to 65. Testosterone has been shown to enhance sexual desire and improve overall sexual functioning, although this use remains off-label.

Despite the potential benefits, accessing testosterone therapy can be challenging for women. Various formulations, including creams, gels, and lozenges, are available; however, the absence of FDA-approved products for women means that clinicians often prescribe male formulations, which may not suit female patients’ needs. This has led to frustrations among women and healthcare providers alike, with reports of prescriptions being denied or delayed by pharmacies.

Looking ahead, over 30 clinical trials investigating testosterone therapy for women are currently underway, with hopes of expanding understanding and acceptance of its benefits beyond just enhancing libido. Dr. Sherry Ross, a women’s health expert, advocates for recognizing testosterone’s role in managing menopause symptoms, emphasizing the need for more research to validate its broader therapeutic applications.

In conclusion, while the increase in testosterone prescriptions for women marks a shift in recognition of female health needs, significant hurdles remain in terms of accessibility and research. Ongoing efforts by the FDA and clinical researchers may pave the way for improved treatment options for women navigating the complexities of menopause.